Traws Pharma announced it will resubmit an updated toxicology data package for tivoxavir marboxil to the UK's MHRA in Q3 2026 to advance a Phase 2a human influenza challenge study. The regulatory progress is material for the clinical-stage biotech's lead antiviral program targeting seasonal influenza and other viral threats.